A
Ajay Padmanaban
Researcher at Apollo Hospitals
Publications - 9
Citations - 221
Ajay Padmanaban is an academic researcher from Apollo Hospitals. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications receiving 23 citations.
Papers
More filters
Journal ArticleDOI
Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.
Marie Warrer Munch,Sheila Nainan Myatra,Bharath Kumar Tirupakuzhi Vijayaraghavan,Sanjith Saseedharan,Thomas Benfield,Rebecka Rubenson Wahlin,Bodil Steen Rasmussen,Anne Sofie Andreasen,Lone Musaeus Poulsen,Luca Cioccari,Mohd Saif Khan,Farhad N Kapadia,Jigeeshu V Divatia,Anne Craveiro Brøchner,Morten H. Bestle,Marie Helleberg,Jens Michelsen,Ajay Padmanaban,Neeta Bose,Anders Pape Møller,Kapil Borawake,Klaus Tjelle Kristiansen,Urvi Shukla,Michelle S Chew,Subhal Dixit,Charlotte Suppli Ulrik,Pravin Amin,Rajesh Chawla,Christian A Wamberg,Mehul S Shah,Iben S Darfelt,Vibeke Lind Jørgensen,Margit Smitt,Anders Granholm,Maj-Brit Nørregaard Kjaer,Morten Hylander Møller,Tine Sylvest Meyhoff,Gitte Kingo Vesterlund,Naomi E Hammond,Naomi E Hammond,Sharon Micallef,Abhinav Bassi,Oommen John,Oommen John,Anubhuti Jha,Maria Cronhjort,Stephan M. Jakob,Christian Gluud,Christian Gluud,Theis Lange,Vaijayanti Kadam,Klaus Marcussen,Jacob Hollenberg +52 more
TL;DR: In this article, the effects of 12 mg vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia were evaluated in a randomized clinical trial at 26 hospitals in Europe and India.
Journal ArticleDOI
Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial.
Anders Granholm,Marie Warrer Munch,Sheila Nainan Myatra,Bharath Kumar Tirupakuzhi Vijayaraghavan,Bharath Kumar Tirupakuzhi Vijayaraghavan,Maria Cronhjort,Rebecka Rubenson Wahlin,Stephan M. Jakob,Luca Cioccari,Maj Brit Nørregaard Kjær,Gitte Kingo Vesterlund,Tine Sylvest Meyhoff,Marie Helleberg,Morten Hylander Møller,Thomas Benfield,Balasubramanian Venkatesh,Naomi E Hammond,Naomi E Hammond,Naomi E Hammond,Sharon Micallef,Abhinav Bassi,Oommen John,Oommen John,Vivekanand Jha,Vivekanand Jha,Vivekanand Jha,Klaus Tjelle Kristiansen,Charlotte Suppli Ulrik,Vibeke Lind Jørgensen,Margit Smitt,Morten H. Bestle,Morten H. Bestle,Anne Sofie Andreasen,Lone Musaeus Poulsen,Bodil Steen Rasmussen,Anne Craveiro Brøchner,Thomas Strøm,Anders Pape Møller,Mohd Saif Khan,Ajay Padmanaban,Jigeeshu V Divatia,Sanjith Saseedharan,Kapil Borawake,Farhad N Kapadia,Subhal Dixit,Rajesh Chawla,Urvi Shukla,Pravin Amin,Michelle S Chew,Christian Aage Wamberg,Christian Gluud,Christian Gluud,Theis Lange,Anders Perner +53 more
TL;DR: In this article, the authors compared dexamethasone 12 versus 6mg daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia in the international, randomised, blinded COVID STEROID 2 trial.
Journal ArticleDOI
Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan.
Marie Warrer Munch,Anders Granholm,Sheila Nainan Myatra,Bharath Kumar Tirupakuzhi Vijayaraghavan,Bharath Kumar Tirupakuzhi Vijayaraghavan,Maria Cronhjort,Rebecka Rubenson Wahlin,Stephan M. Jakob,Luca Cioccari,Maj Brit Nørregaard Kjær,Gitte Kingo Vesterlund,Tine Sylvest Meyhoff,Marie Helleberg,Morten Hylander Møller,Thomas Benfield,Balasubramanian Venkatesh,Naomi E Hammond,Sharon Micallef,Abhinav Bassi,Oommen John,Oommen John,Vivekanand Jha,Vivekanand Jha,Vivekanand Jha,Klaus Tjelle Kristiansen,Charlotte Suppli Ulrik,Vibeke Lind Jørgensen,Margit Smitt,Morten H. Bestle,Morten H. Bestle,Anne Sofie Andreasen,Lone Musaeus Poulsen,Bodil Steen Rasmussen,Anne Craveiro Brøchner,Thomas Strøm,Anders Pape Møller,Mohd Saif Khan,Ajay Padmanaban,Jigeeshu V Divatia,Sanjith Saseedharan,Kapil Borawake,Farhad N Kapadia,Subhal Dixit,Rajesh Chawla,Urvi Shukla,Pravin Amin,Michelle S. Chew,Christian Gluud,Theis Lange,Anders Perner +49 more
TL;DR: The COVID STEROID 2 trial as discussed by the authors is an investigator-initiated, international, parallel-grouped, blinded, centrally randomised and stratified clinical trial assessing higher (12 mg) vs. lower (6 mg) doses of dexamethasone for adults with COVID-19 and severe hypoxia.
Journal ArticleDOI
Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia
Anders Granholm,Maj Brit Nørregaard Kjær,Marie Warrer Munch,Sheila Nainan Myatra,Bharath Kumar Tirupakuzhi Vijayaraghavan,Maria Cronhjort,Rebecka Rubenson Wahlin,Stephan M. Jakob,Luca Cioccari,Gitte Kingo Vesterlund,Tine Sylvest Meyhoff,Marie Helleberg,Morten Hylander Møller,Thomas Benfield,Balasubramanian Venkatesh,Naomi E Hammond,Sharon Micallef,A. Bassi,Oommen John,Vivekanand Jha,Klaus Tjelle Kristiansen,Charlotte Suppli Ulrik,Vibeke Lind Jørgensen,Margit Smitt,Morten H. Bestle,Anne Sofie Andreasen,Lone Musaeus Poulsen,Bodil Steen Rasmussen,Anne Craveiro Brøchner,Thomas Strøm,Anders Møller,Mohd Saif Khan,Ajay Padmanaban,Jigeeshu V Divatia,Sanjith Saseedharan,Kapil Borawake,Farhad N Kapadia,Subhal Dixit,Rajesh Chawla,Urvi Shukla,Pravin Amin,Michelle S Chew,Christian Wamberg,Neeta Bose,Mehul S. Shah,Iben S. Darfelt,Christian Gluud,Theis Lange,Anders Perner +48 more
TL;DR: In this article , the authors assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.
Journal ArticleDOI
Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis.
Anders Granholm,Marie Warrer Munch,Sheila Nainan Myatra,Bharath Kumar Tirupakuzhi Vijayaraghavan,Bharath Kumar Tirupakuzhi Vijayaraghavan,Maria Cronhjort,Rebecka Rubenson Wahlin,Stephan M. Jakob,Luca Cioccari,Maj Brit Nørregaard Kjær,Gitte Kingo Vesterlund,Tine Sylvest Meyhoff,Marie Helleberg,Morten Hylander Møller,Thomas Benfield,Balasubramanian Venkatesh,Naomi E Hammond,Sharon Micallef,Abhinav Bassi,Oommen John,Oommen John,Vivekanand Jha,Vivekanand Jha,Vivekanand Jha,Klaus Tjelle Kristiansen,Charlotte Suppli Ulrik,Vibeke Lind Jørgensen,Margit Smitt,Morten H. Bestle,Morten H. Bestle,Anne Sofie Andreasen,Lone Musaeus Poulsen,Bodil Steen Rasmussen,Anne Craveiro Brøchner,Thomas Strøm,Anders Pape Møller,Mohd Saif Khan,Ajay Padmanaban,Jigeeshu V Divatia,Sanjith Saseedharan,Kapil Borawake,Farhad N Kapadia,Subhal Dixit,Rajesh Chawla,Urvi Shukla,Pravin Amin,Michelle S. Chew,Christian Gluud,Theis Lange,Anders Perner +49 more
TL;DR: In this article, a secondary, pre-planned Bayesian analysis of the primary outcome (days alive without life support at day 28) and all secondary outcomes registered up to day 90 was presented.